Related Experiment Video
Updated: Jun 21, 2025

06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.4K
Novel treatments in optic pathway gliomas
Akash Maheshwari1,2,3, Mohammad Pakravan1, Chaow Charoenkijkajorn1
1Department of Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital, Houston, TX, United States.
Frontiers in Ophthalmology
|July 10, 2024
Summary
Optic pathway gliomas (OPG), often linked to neurofibromatosis type 1, typically show benign pathology but have varied clinical courses. Management ranges from observation to chemotherapy, radiotherapy, or surgery based on individual cases.
Area of Science:
- Neuro-oncology
- Ophthalmology
- Genetics
Background:
- Optic pathway gliomas (OPG) are primary tumors affecting the optic nerve, chiasm, and tract.
- These tumors are frequently associated with neurofibromatosis type 1 (NF1).
- OPGs typically exhibit benign histopathology but present with a variable clinical course.
Purpose of the Study:
- To review the current literature on optic pathway gliomas.
- To highlight recent advancements in the treatment strategies for OPG.
Main Methods:
- Comprehensive literature review of OPG.
- Emphasis on recent therapeutic developments.
Main Results:
- Observation is the recommended initial approach for stable or age-normal vision.
- Treatment options include chemotherapy, radiotherapy, and surgery for select cases.
- Recent developments focus on refining these treatment modalities.
Conclusions:
- Optic pathway gliomas require careful management due to their variable clinical course.
- Treatment decisions are individualized based on tumor characteristics and patient status.
- Ongoing research aims to improve outcomes for OPG patients.
Keywords:
BRAF inhibitorMEK inhibitorbevacizumabchemotherapyimmunotherapylow grade gliomaoptic pathway gliomastereotactic radiation
